Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Would Proposed New Rule for Repricing Long-Listed Drugs Create Winners and Losers? Bill Payers Opposed, Industry Watching Closely
December 5, 2013
- PAFSC’s First Committee Backs Japan’s 1st SGLT-2 Inhibitor
December 2, 2013
- 11 APIs/33 Products Including ComPlavin Added to NHI Price List
December 2, 2013
- PFSB Issues Notification Calling for Revisions of Package Inserts for Drugs Including Aricept, Cravit
December 2, 2013
- Toned-Down Proposal on “Precursor” Premium Still Leaves CSIMC Wary; 10% Tabled with Strings Attached
November 29, 2013
- New Proposals by Regulatory Reform Council Include Elimination of 14-Day Prescription Limit
November 29, 2013
- New Combination Drugs Containing Non-Innovative APIs Should Be Priced Based on Prices of Other APIs Contained: CSIMC Subcommittee
November 29, 2013
- CSIMC Bill Payer Rep Repeats Opposition to Replacing Special Price Cut for Off-Patent Drugs with New Rule
November 28, 2013
- Ministry Revises Plan to Set First Generic Prices, Suggests 50% or 60%
November 28, 2013
- MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
- RMPs Required for Generics when RMPs Submitted for Original Products: Health Ministry
November 27, 2013
- Nearly 60% of Face-to-Face Consultations from July 2011 through September 2013 Involved Drugs: PMDA
November 26, 2013
- Subcommittee Agrees to Introduction of New Price Reduction Rule for Long-Listed Drugs Next Year; Will Continue to Discuss Details
November 22, 2013
- JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
- Upper House Passes Amended Pharmaceutical Affairs Law and Law to Ensure Safety of Regenerative Medicine
November 21, 2013
- Decision on Long-Term Prescriptions to Be Based on Results of Discussions at CSIMC: Government
November 21, 2013
- Plan Floated to Merge NIBIO Unit, JST to Create Japan-Version NIH: Govt Source
November 20, 2013
- Finance Minister Pushes Drastic Price Cuts for Off-Patent Drugs with Low Generic Penetration
November 20, 2013
- Administrative Reform Council Calls for Further Promotion of Generics, Elimination of OTC-like Drugs from Insurance Coverage
November 20, 2013
- PAFSC’s Second Committee Supports Approval of NBI’s Lung Cancer Drug, Takeda’s Malignant Lymphoma Treatment
November 19, 2013
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…